Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Scisparc Ltd
SPRC
Healthcare
Drug Manufacturers - Specialty & Generic
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and...
the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:SPRC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
(306)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Sep 18, 2024 4:15pm
SciSparc Takes Major Step Forward with IND Application submi
News; $SPRC SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome TreatmentYale Child Study Center at the Yale School of
...more
(306)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 29, 2024 5:45pm
SciSparc-Clearmind Medicine Collaboration Leads to Publicati
Just In: $SPRC SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based CombinationTEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.
...more
(306)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 16, 2024 5:30pm
SciSparc Finalizes Exclusive Global Out-Licensing Agreement
NEWS: $SPRC SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 millionSciSparc will receive consideration in shares, and in addition may receive cash
...more
(59)
•••
Nibinator
X
View Profile
View Bullboard History
Post by
Nibinator
on Jul 25, 2024 1:17pm
BUY BUY BUY BUY BUY
Very likely to pop to 2$ sonner than later
(306)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 11, 2024 12:15pm
SciSparc to Acquire AutoMax
BREAKING NEWS: $SPRC SciSparc to Acquire AutoMaxTEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical
...more
(306)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 20, 2024 1:45pm
What's Going On With Psychedelic Drug-Developers SciSparc An
Breaking News: $SPRC What's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock? | BenzingaSciSparc Ltd. (NASDAQ:SPRC) and Clearmind Medicine Inc. (NASDAQ:CMND) shares are
...more
(306)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 20, 2024 11:00am
SciSparc and Clearmind Continue to Strengthen International
NEWS: $SPRC SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based CompoundsTEL AVIV, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE
...more
(306)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 24, 2024 10:15am
SciSparc Ltd. Announces $20 Million Standby Equity Purchase
News; $SPRC SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement | BenzingaTEL AVIV, Israel, Jan. 24, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 13, 2023 8:18am
New Press Release - SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
MitoCareX Bio met its second milestone as part of its joint venture agreement with the CompanyTEL AVIV, Israel, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 07, 2023 9:05am
New Press Release - SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
TEL AVIV, Israel, Dec. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today updates...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 01, 2023 8:14am
New Press Release - Weight Loss Treatment: SciSparc's Obesity Drug Showed Positive Results in a Pre-Clinical Trial
The collaboration between SciSparc and Clearmind continues to yield positive results in its obesity and metabolic disorder programTEL AVIV, Israel, Dec. 01, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 28, 2023 8:55am
New Press Release - SciSparc Adopts Limited Duration Shareholder Rights Plan
TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 28, 2023 8:25am
New Press Release - SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI moleculeTEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company...
read article.
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Nov 27, 2023 8:43am
SPRC....early a.m runner on NR
"I want to take you higher" Sheesh !!!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 27, 2023 8:41am
New Press Release - SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
MitoCareX Bio has met its second milestone as part of its joint venture agreement with the CompanyTEL AVIV, Israel, Nov. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
read article.
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Alphamin Announces Record Fy2024 & Q4 2024 Tin Production Fy2025 Production Guidance Exploration Success
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*
Eminent's First Drill Hole Hits Significant Gold-Arsenic in Getchell Trend Analogue and Second Hole Drilling Commences
U.S. DOD Logistics Agency Highlights V.GPH Project to Develop Eco-Friendly Graphite-Based Fire-Fighting Material
Have you held units of a TD mutual fund, other than through a discount broker? Learn more.